Kim J.M. van der Velden

Dr. Kim J.M. van der Velden

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
NSNori Smeets
Nori Smeets
ETEsther M. M. Teunissen
Esther M. M. Teunissen
KVKim J.M. van der Velden
Kim J.M. van der Velden
MBMaurice J. P. van der Burgh
Maurice J. P. van der Burgh
DLDemi E. Linders
Demi E. Linders
Saskia N. de WildtSaskia N. de Wildt
Saskia N. de Wildt
Background: Acute kidney injury (AKI) and augmented renal clearance (ARC), both alterations of the glomerular filtration rate (GFR), are prevalent in critically ill children and neonates. AKI and ARC prevalence estimates are based on estimation of GFR (eGFR) using serum creatinine (SCr), which is known to be inaccurate. We aimed to test our hypothesis that AKI prevalence will be higher and ARC prevalence will be lower in critically ill children when using iohexol-based measured GFR (mGFR), rather than using eGFR. Additionally, we aimed to investigate the performance of different SCr-based eGFR methods. Methods: In this single-center prospective study, critically ill term-born neonates and children were included. mGFR was calculated using a plasma disappearance curve after parenteral administration of iohexol. AKI diagnosis was based on the KDIGO criteria, SCr-based eGFR, and creatinine clearance (CrCL). Differences between eGFR and mGFR were determined using Wilcoxon signed-rank tests and by calculating bias and accuracy (percentage of eGFR values within 30% of mGFR values). Results: One hundred five children, including 43 neonates, were included. AKI prevalence was higher based on mGFR (48%), than with KDIGO or eGFR (11–40%). ARC prevalence was lower with mGFR (24%) compared to eGFR (38–51%). eGFR equations significantly overestimated mGFR (60–71 versus 41 ml/min/1.73 m2, p < 0.001–0.002). Accuracy was highest with eGFR equations based on age- and sex-dependent equations (up to 59%). Conclusion: Iohexol-based AKI prevalence was higher and ARC prevalence lower compared to standard SCr-based eGFR methods. Age- and sex-dependent equations for eGFR (eGFR-Smeets for neonates and eGFR-Pierce for children) best approached measured GFR and should preferably be used to optimize diagnosis of AKI and ARC in this population. Graphical A higher resolution version of the Graphical abstract is available as Supplementary information

18 February 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
Dianne BoschDianne Bosch
Dianne Bosch
KVKim J.M. van der Velden
Kim J.M. van der Velden
TBTom Belleman
Tom Belleman
WDWelmoed K. van Deen
Welmoed K. van Deen
ABAndries Bergman
Andries Bergman
IOInge M. van Oort
Inge M. van Oort
Androgen receptor targeted therapies (ART) play a major role in the treatment of metastatic castration-resistant prostate cancer (mCRPC). In recent years consensus has been reached that treatment with a second ART should be avoided due to low response rates. The aim of this study was to investigate if new scientific insights led to changes in clinical daily practice in the Netherlands. Patients included in the Dutch CAPRI-3 prostate cancer registry, currently encompassing 19 hospitals, and treated with at least 1 ART (ie, abiraterone or enzalutamide) were included. Patients were stratified based on start date of first ART (ART1) according to standard of care between 2016-2017, 2018-2019 and 2020-2021. Second ART (ART2) was defined as either direct (ART1>ART2) or at any given time (any ART2). Between the first and last ART1 group, the prevalence of ART1>ART2 declined from 14.3% to 6.5% (P = .001) and the prevalence of any ART2 from 27.6% to 10.7% (P < .001). The decline was observed before recommendations were included in European guidelines. The use of other life-prolonging drugs (LPDs) after ART1 (ART1>LPD) increased. Patients who were selected for ART1>ART2 instead of ART1>LPD were older, less frequently treated with taxane-based chemotherapy for mHSPC and had a longer time to development of mCRPC. New scientific insights were incorporated into clinical daily practice, with a significant decline in in the prevalence of sequential ART treatment, even before recommendations were included in European guidelines.

10 July 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
KVKim J.M. van der Velden
Kim J.M. van der Velden
DBD. Bosch
D. Bosch
ZVZ. Vassilev
Z. Vassilev
ABA. M. Bergman
A. M. Bergman
ABA. C. M. van Den Bergh
A. C. M. van Den Bergh
IOI. M. van Oort
I. M. van Oort
Purpose: Since 2019, EAU guidelines recommend PSMA-PET/CT for staging high-risk prostate cancer. However, real-world data on its uptake and association with disease characteristics and outcomes in metastatic castration-sensitive prostate cancer (mCSPC) remains limited. We evaluated real-world PSMA-PET/CT use versus conventional imaging (CI). Methods: This retrospective study included 3,644 mCSPC patients (2016–2021) from 19 hospitals in the Dutch CAPRI-3 registry. Staging within 90 days of diagnosis was classified as CI-only (CT, bone scintigraphy, and/or MRI) or PSMA-PET (± CI). Results: Most patients were staged with CI-only (63%), but PSMA-PET use rose from 8% in 2016 to 62% in 2021. PSMA-PET-staged patients were younger (72 vs. 76 years) and had significantly lower tumour burden (27% vs. 45% high-volume), more nodal-only disease, and were more likely to have metachronous presentation (29% vs. 22%, all P < 0.001). In the PSMA-PET group, 42% received ADT plus targeted therapy and 23% ADT monotherapy (vs. 45% ADT monotherapy in CI-only). Median overall survival was significantly longer in the PSMA-PET cohort (78.3 vs. 40.0 months). Conclusion: There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.

4 November 2026 in Tijdschrift voor Urologie
Verified
Journal Article
Open access
PDF file
KVKim J.M. van der Velden
Kim J.M. van der Velden
DBDianne Bosch
Dianne Bosch
ZVZdravko Vassilev
Zdravko Vassilev
ABAndries M. Bergman
Andries M. Bergman
ABAlfons C. M. van Den Bergh
Alfons C. M. van Den Bergh
IOInge M. van Oort
Inge M. van Oort
Samenvatting: Doel: Sinds 2019 adviseren de EAU-richtlijnen PSMA-PET/CT voor stadiëring van hoogrisicoprostaatkanker, maar real-worlddata over de impact bij mCSPC zijn beperkt. Dit onderzoek evalueert real-worldgebruikstrends, patiëntkenmerken en behandelkeuze bij PSMA-PET/CT versus conventionele beeldvorming (CB). Methode: mCSPC-patiënten (2016–2021) uit 19 ziekenhuizen in het CAPRI-3-register werden geïncludeerd. Beeldvorming binnen 90 dagen na diagnose werd geclassificeerd als uitsluitend CB (CT, botscan of MRI) of PSMA-PET (PSMA-PET/CT ± CB). Resultaten: Van de 3.644 patiënten werd 63 % gestadieerd met uitsluitend CB, maar PSMA-PET-gebruik steeg van 8 % naar 62 % (2016–2021). PSMA-PET-patiënten waren jonger, met vaker nodale-only- en laagvolumeziekte (alle p < 0,001), kregen vaker lokale therapie of afwachtend beleid, en hadden een langere overleving (78,3 versus 40,0 maanden). Conclusie: Deze stadiëringsmigratie identificeert een populatie met een gunstiger prognose en beïnvloedt behandelselectie; correctie voor selectiebias (Will Rogers-fenomeen) is essentieel bij overlevingsvergelijkingen.

31 March 2026 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
Giuseppe VerolinoGiuseppe Verolino
Giuseppe Verolino
KVKim J.M. van der Velden
Kim J.M. van der Velden
BSBarthel W Sauren
Barthel W Sauren
SKSuzanne Kats
Suzanne Kats
RLRoberto Lorusso
Roberto Lorusso
Background: We present a successful case of triple-valve surgery, including bailout open-heart transcatheter mitral valve implantation, in a haemodialysis patient with extensive intracardiac calcifications. Case summary: A middle-aged woman with exercise-induced dyspnoea and an end-stage kidney disease on renal replacement therapy was admitted to the emergency department for severe hypotension and bradycardia. A high-degree AV block was diagnosed. Multimodal imaging exams also revealed a triple severe valvular disease (mitral stenosis, aortic stenosis, and tricuspid regurgitation) with an unclear cardiac mass enclosed within the left atrial wall. To avoid potentially dangerous decalcification for valve replacement, a combined traditional surgical approach and transcatheter valve implantation have been successfully applied. Discussion: The current case confirms that open-heart transcatheter valve implantation at the mitral position in the presence of marked calcifications involving the valve apparatus, atrial, and ventricular walls is a valuable option, potentially avoiding dangerous decalcification, achieving effective mitral valve stenosis relief, and shortening surgical times.